These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 18006696

  • 1. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.
    Chen L, Monti S, Juszczynski P, Daley J, Chen W, Witzig TE, Habermann TM, Kutok JL, Shipp MA.
    Blood; 2008 Feb 15; 111(4):2230-7. PubMed ID: 18006696
    [Abstract] [Full Text] [Related]

  • 2. FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.
    Szydlowski M, Kiliszek P, Sewastianik T, Jablonska E, Bialopiotrowicz E, Gorniak P, Polak A, Markowicz S, Nowak E, Grygorowicz MA, Prochorec-Sobieszek M, Szumera-Cieckiewicz A, Malenda A, Lech-Maranda E, Warzocha K, Juszczynski P.
    Blood; 2016 Feb 11; 127(6):739-48. PubMed ID: 26585955
    [Abstract] [Full Text] [Related]

  • 3. BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.
    Juszczynski P, Chen L, O'Donnell E, Polo JM, Ranuncolo SM, Dalla-Favera R, Melnick A, Shipp MA.
    Blood; 2009 Dec 17; 114(26):5315-21. PubMed ID: 19855081
    [Abstract] [Full Text] [Related]

  • 4. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.
    Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG, Gandhi V, Burger JA.
    Blood; 2009 Jul 30; 114(5):1029-37. PubMed ID: 19491390
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.
    Gobessi S, Laurenti L, Longo PG, Carsetti L, Berno V, Sica S, Leone G, Efremov DG.
    Leukemia; 2009 Apr 30; 23(4):686-97. PubMed ID: 19092849
    [Abstract] [Full Text] [Related]

  • 6. Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation.
    Chen L, Juszczynski P, Takeyama K, Aguiar RC, Shipp MA.
    Blood; 2006 Nov 15; 108(10):3428-33. PubMed ID: 16888096
    [Abstract] [Full Text] [Related]

  • 7. SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas.
    Chen L, Monti S, Juszczynski P, Ouyang J, Chapuy B, Neuberg D, Doench JG, Bogusz AM, Habermann TM, Dogan A, Witzig TE, Kutok JL, Rodig SJ, Golub T, Shipp MA.
    Cancer Cell; 2013 Jun 10; 23(6):826-38. PubMed ID: 23764004
    [Abstract] [Full Text] [Related]

  • 8. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
    Buchner M, Baer C, Prinz G, Dierks C, Burger M, Zenz T, Stilgenbauer S, Jumaa H, Veelken H, Zirlik K.
    Blood; 2010 Jun 03; 115(22):4497-506. PubMed ID: 20335218
    [Abstract] [Full Text] [Related]

  • 9. Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.
    Bernard S, Danglade D, Gardano L, Laguillier C, Lazarian G, Roger C, Thieblemont C, Marzec J, Gribben J, Cymbalista F, Varin-Blank N, Ledoux D, Baran-Marszak F.
    Int J Cancer; 2015 Jun 15; 136(12):2761-74. PubMed ID: 25388373
    [Abstract] [Full Text] [Related]

  • 10. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.
    Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E, Lau A, Young C, Wong BR, Lovell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, Singh R, Grossbard EB, Payan DG, Masuda ES.
    J Pharmacol Exp Ther; 2006 Dec 15; 319(3):998-1008. PubMed ID: 16946104
    [Abstract] [Full Text] [Related]

  • 11. Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma.
    Ma J, Xing W, Coffey G, Dresser K, Lu K, Guo A, Raca G, Pandey A, Conley P, Yu H, Wang YL.
    Oncotarget; 2015 Dec 22; 6(41):43881-96. PubMed ID: 26575169
    [Abstract] [Full Text] [Related]

  • 12. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.
    Mandato E, Nunes SC, Zaffino F, Casellato A, Macaccaro P, Tubi LQ, Visentin A, Trentin L, Semenzato G, Piazza F.
    Curr Cancer Drug Targets; 2018 Dec 22; 18(6):608-616. PubMed ID: 28460620
    [Abstract] [Full Text] [Related]

  • 13. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.
    Goldstein RL, Yang SN, Taldone T, Chang B, Gerecitano J, Elenitoba-Johnson K, Shaknovich R, Tam W, Leonard JP, Chiosis G, Cerchietti L, Melnick A.
    J Clin Invest; 2015 Nov 03; 125(12):4559-71. PubMed ID: 26529251
    [Abstract] [Full Text] [Related]

  • 14. Quantitative immunofluorescence reveals the signature of active B-cell receptor signaling in diffuse large B-cell lymphoma.
    Bogusz AM, Baxter RH, Currie T, Sinha P, Sohani AR, Kutok JL, Rodig SJ.
    Clin Cancer Res; 2012 Nov 15; 18(22):6122-35. PubMed ID: 22966017
    [Abstract] [Full Text] [Related]

  • 15. SYK inhibition and response prediction in diffuse large B-cell lymphoma.
    Cheng S, Coffey G, Zhang XH, Shaknovich R, Song Z, Lu P, Pandey A, Melnick AM, Sinha U, Wang YL.
    Blood; 2011 Dec 08; 118(24):6342-52. PubMed ID: 22025527
    [Abstract] [Full Text] [Related]

  • 16. CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas.
    Chen L, Ouyang J, Wienand K, Bojarczuk K, Hao Y, Chapuy B, Neuberg D, Juszczynski P, Lawton LN, Rodig SJ, Monti S, Shipp MA.
    Haematologica; 2020 May 08; 105(5):1361-1368. PubMed ID: 31471373
    [Abstract] [Full Text] [Related]

  • 17. Tonic B-cell receptor signaling in diffuse large B-cell lymphoma.
    Havranek O, Xu J, Köhrer S, Wang Z, Becker L, Comer JM, Henderson J, Ma W, Man Chun Ma J, Westin JR, Ghosh D, Shinners N, Sun L, Yi AF, Karri AR, Burger JA, Zal T, Davis RE.
    Blood; 2017 Aug 24; 130(8):995-1006. PubMed ID: 28646116
    [Abstract] [Full Text] [Related]

  • 18. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
    Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM.
    Nature; 2010 Jan 07; 463(7277):88-92. PubMed ID: 20054396
    [Abstract] [Full Text] [Related]

  • 19. Immunotoxicity assessment for the novel Spleen tyrosine kinase inhibitor R406.
    Zhu Y, Herlaar E, Masuda ES, Burleson GR, Nelson AJ, Grossbard EB, Clemens GR.
    Toxicol Appl Pharmacol; 2007 Jun 15; 221(3):268-77. PubMed ID: 17490694
    [Abstract] [Full Text] [Related]

  • 20. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
    Myklebust JH, Brody J, Kohrt HE, Kolstad A, Czerwinski DK, Wälchli S, Green MR, Trøen G, Liestøl K, Beiske K, Houot R, Delabie J, Alizadeh AA, Irish JM, Levy R.
    Blood; 2017 Feb 09; 129(6):759-770. PubMed ID: 28011673
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.